세계의 동물용 생물학적 제제 시장 보고서(2025년)
Veterinary Biologics Global Market Report 2025
상품코드 : 1793411
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

동물용 생물학적 제제 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.8%로 183억 6,000만 달러로 성장할 것입니다. 예측 기간의 성장은 신흥 전염병, 기후변화와 질병 패턴, 정밀 축산, 원헬스 접근법, 반려동물 사육 트렌드 증가 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 교육 및 훈련 프로그램, 친환경적이고 지속가능한 생물학적 제제, 디지털 건강 기록의 통합, 반려동물 생물학적 제제의 증가, 맞춤형 표적 치료 등이 있습니다.

향후 5년간의 성장률 7.8%라는 예측은 지난번 이 시장에 대한 예측과 다르지 않습니다. 이 감소의 주요 원인은 미국과 다른 국가 간의 관세의 영향입니다. 재조합 단백질, 세포주 등 중요한 생물학적 제제 투입에 대한 무역 장벽은 생산의 확장성을 저해하고 수의학 생물학의 개발 일정을 지연시킬 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것입니다.

동물 질병의 급증은 동물용 생물학적 제제 시장 성장의 원동력이 될 것으로 예상됩니다. 동물 질병에는 다양한 동물 종에 영향을 미치는 다양한 질병이 포함됩니다. 이러한 질병의 증가는 첨단 진단 및 치료 솔루션의 필요성을 강조하고 있으며, 동물 질병에 대처하고 관리하는 면역학적 방법을 채택한 수의생물학이 그 수요에 부응하고 있습니다. 2022년 10월 현재 유럽질병예방통제센터는 2,467건의 가금류 조류인플루엔자 발생을 보고했으며, 4,800만 마리의 가금류가 영향을 받았다고 보고했습니다. 이와 관련해 세계보건기구(WHO)는 2022년 7월 광견병이 150여 개국에서 연간 5만 9,000명의 목숨을 앗아가고 있다고 밝혔습니다. 이러한 동물 질병의 급증은 동물용 생물학적 제제 시장을 견인하는 매우 중요한 요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Veterinary biologics encompass biological products obtained from living organisms such as viruses, bacteria, or other microorganisms. These specialized products in veterinary medicine serve to prevent, diagnose, or treat diseases in animals.

Key products falling under veterinary biologics include vaccines, diagnostic kits, immunomodulators, antiserums, antibodies, and related items. Vaccines, for instance, are formulated to trigger the immune system's response and offer protection against specific animal diseases. They address various ailments such as bluetongue, foot and mouth disease, brucellosis, tuberculosis, and others. These products are distributed through multiple channels, including veterinary hospitals and clinics, for diverse applications involving both production and companion animals.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The rapid escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a considerable impact on the veterinary healthcare sector, particularly in the supply of pharmaceuticals, medical devices, and animal care products. Increased duties on imported veterinary medicines, diagnostic equipment, surgical tools, and pet care supplies have driven up operational costs for veterinary clinics, animal hospitals, and livestock health providers, forcing them to either raise service charges or absorb reduced profit margins. The livestock and agricultural industries are facing similar pressures, as tariffs on feed additives, vaccines, and breeding equipment push up production costs and complicate animal health management. Furthermore, retaliatory tariffs in major export markets have weakened demand for U.S.-manufactured veterinary products, adding to revenue challenges. To navigate these headwinds, the sector must now focus on local sourcing, preventive healthcare strategies, and digital veterinary solutions to control costs while continuing to deliver quality animal care.

The veterinary biologics market research report is one of a series of new reports from The Business Research Company that provides veterinary biologics market statistics, including veterinary biologics industry global market size, regional shares, competitors with a veterinary biologics market share, detailed veterinary biologics market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary biologics industry. This veterinary biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The veterinary biologics market size has grown strongly in recent years. It will grow from $12.67 billion in 2024 to $13.61 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to animal disease outbreaks, regulatory support and standards, demand for food safety, globalization of trade, and economic significance of livestock.

The veterinary biologics market size is expected to see strong growth in the next few years. It will grow to $18.36 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to emerging infectious diseases, climate change and disease patterns, precision livestock farming, one health approach, and increased pet ownership trends. Major trends in the forecast period include education and training programs, eco-friendly and sustainable biologics, integration of digital health records, rise in companion animal biologics, and customized and targeted therapies.

The forecast of 7.8% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade barriers on critical biologic inputs, such as recombinant proteins and cell lines, could hinder production scalability and delay veterinary biologics development timelines. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The upsurge in the prevalence of animal diseases is anticipated to be a driving force behind the growth of the veterinary biologics market. Animal diseases encompass a range of illnesses affecting diverse animal species. The escalation in these diseases underscores the need for advanced diagnostic and treatment solutions, a demand met by veterinary biologics that employ immunological methods to address and manage animal diseases. As of October 2022, the European Center for Disease Prevention and Control reported 2,467 outbreaks of avian influenza in poultry, impacting 48 million birds, with an additional 187 cases observed in captive birds. In a related context, the World Health Organization disclosed in July 2022 that rabies claims the lives of 59,000 people annually across over 150 countries, with a predominant 95% of cases concentrated in Africa and Asia. This surge in animal diseases is a pivotal factor propelling the veterinary biologics market.

The increasing trend of pet adoption is poised to contribute significantly to the growth of the veterinary biologics market. Pet adoption involves assuming responsibility for a domesticated animal, often from shelters or rescue organizations, to provide a permanent and caring home. Veterinary biologics play a crucial role in preventing infectious diseases in pets, offering immunity, controlling zoonotic diseases, enhancing lifespan and quality of life, reducing veterinary healthcare costs, improving reproductive health in pets, and providing more targeted and customized treatment options. Data from October 2023, as reported by the American Pet Products Association, reveals that 66% of U.S. households, totaling 86.9 million, own a pet-an increase from 62% in 2022. This surge in pet adoption is a significant driver behind the expanding veterinary biologics market.

Leading companies in the veterinary biologics market are concentrating on the development of innovative biologics, such as vaccines, to improve animal health and prevent diseases. A vaccine is a substance that triggers the immune system to recognize and combat specific pathogens, helping to prevent infectious diseases by providing acquired immunity. For example, in August 2024, Merck Animal Health, a global animal health company based in the U.S., launched an experimental autogenous vaccine targeting avian metapneumovirus (aMPV) type B, which received approval from the U.S. Department of Agriculture (USDA) for manufacturing and sale. Created in partnership with Cambridge Technologies, this vaccine aims to address the serious respiratory problems caused by aMPV type B in poultry, which have resulted in significant economic losses since late 2023. Manufactured at a state-of-the-art facility in Minnesota, the vaccine uses an oil and water emulsion formulation designed to reduce post-vaccination tissue reactions, filling a crucial gap in the market as there were previously no commercially licensed vaccines available.

Companies at the forefront of the veterinary biologics market are also channeling their efforts into the creation of innovative products, such as injections designed to control pain associated with osteoarthritis (OA) in dogs. These injections target canine nerve growth factors, providing an effective means to alleviate the pain that dogs experience due to osteoarthritis. Zoetis Inc., a distinguished U.S.-based animal health company, secured approval from the U.S. Food and Drug Administration (FDA) for Librela (bedinvetmab injection) in May 2023. Positioned as the first and only monthly anti-NGF monoclonal antibody medication for canine OA pain, Librela stands out as a safe and efficacious solution for managing long-term OA pain symptoms in dogs. This approval underscores Librela's role in enhancing the mobility and overall well-being of canines grappling with osteoarthritis, contributing to an improved quality of life for these animals.

In January 2024, Ceva Sante Animale, a pharmaceutical company based in France, acquired Scout Bio for an undisclosed amount. This acquisition enhances Ceva's biotechnology capabilities and speeds up its innovation in pet therapeutics, particularly targeting advanced treatments for chronic diseases. This strategic move responds to the growing demand for better health solutions among pet owners. Scout Bio is a biotechnology company located in the U.S. that specializes in providing essential data for the development of effective veterinary biologics, including vaccines and diagnostics.

Major companies operating in the veterinary biologics market include Bayer AG, Eli Lilly & Company, Evonik Industries AG, Zoetis Inc., Merck Animal Health Inc., Boehringer Ingelheim Animal Health Inc., Elanco Animal Health, IDEXX Laboratories Inc., Virbac SA, Phibro Animal Health Corporation, Vetoquinol, Abaxis Inc., Bimeda Biologicals, Ceva Sante Animale S.A., Heska Corporation, Colorado Serum Company, Hester Biosciences Limited, INDICAL Bioscience GmbH, Ambrx Biopharma Inc., Adamis Pharmaceuticals Corporation, Intervet Inc., Hebei Veyong Animal Pharmaceutical Co. Ltd., FidoCure, Biomet Biologics LLC, CytoDyn Veterinary Medicine LLC, KM Biologics

North America was the largest region in the veterinary biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the veterinary biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The veterinary biologics market consists of sales of transplant tissues, recombinant proteins, and stem cells. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Veterinary Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on veterinary biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for veterinary biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The veterinary biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Veterinary Biologics Market Characteristics

3. Veterinary Biologics Market Trends And Strategies

4. Veterinary Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Veterinary Biologics Growth Analysis And Strategic Analysis Framework

6. Veterinary Biologics Market Segmentation

7. Veterinary Biologics Market Regional And Country Analysis

8. Asia-Pacific Veterinary Biologics Market

9. China Veterinary Biologics Market

10. India Veterinary Biologics Market

11. Japan Veterinary Biologics Market

12. Australia Veterinary Biologics Market

13. Indonesia Veterinary Biologics Market

14. South Korea Veterinary Biologics Market

15. Western Europe Veterinary Biologics Market

16. UK Veterinary Biologics Market

17. Germany Veterinary Biologics Market

18. France Veterinary Biologics Market

19. Italy Veterinary Biologics Market

20. Spain Veterinary Biologics Market

21. Eastern Europe Veterinary Biologics Market

22. Russia Veterinary Biologics Market

23. North America Veterinary Biologics Market

24. USA Veterinary Biologics Market

25. Canada Veterinary Biologics Market

26. South America Veterinary Biologics Market

27. Brazil Veterinary Biologics Market

28. Middle East Veterinary Biologics Market

29. Africa Veterinary Biologics Market

30. Veterinary Biologics Market Competitive Landscape And Company Profiles

31. Veterinary Biologics Market Other Major And Innovative Companies

32. Global Veterinary Biologics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Veterinary Biologics Market

34. Recent Developments In The Veterinary Biologics Market

35. Veterinary Biologics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기